Dynavax helps advance COVID-19 vaccine candidates

By The Science Advisory Board staff writers

Dynavax Technologies said it will be providing additional quantities of its CpG 1018 adjuvant for Valneva's SARS-CoV-2 vaccine candidate and has also signed a deal to supply CpG 1018 to the Coalition for Epidemic Preparedness (CEPI).

Valneva reserved enough CpG 1018 to support 40 million additional doses of VLA2001 that have been ordered by the U.K. government. As a result of the U.K. contract, Valneva has now reserved quantities of CpG 1018 sufficient to support production of 100 million doses of VLA2001 in 2021, according to Dynavax.

In other Dynavax news, the company said that it signed a deal with CEPI to supply CpG 1018 for approved COVID-19 vaccines developed by CEPI grantees.

Under the terms of the deal, CEPI will provide a forgivable loan of up to $99 million for manufacturing of CpG 1018 with the potential to support hundreds of million doses of COVID-19 vaccines for delivery in 2021 through the global COVID-19 vaccine supply initiative COVAX. Dynavax would sell the reserved CpG 1018 under separate commercial supply agreements made directly with CEPI grantees, according to the company.

Copyright © 2021 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking